• Home
  • Getting Started
    • ChartMill OverviewGrowth TradersTechnical Swing Traders Long Term Investors
  • Tools
    • Stock ScreenerStock ChartsFull Screen Stock ChartsMarket MonitorSectorsEarningsAnalyzerInsider TradingUp- and Downgrades
  • Stock Market
    • Top Gainers and LosersNew 52 Week High and LowGap Up and Gap DownMost ActivePremarket MoversAfter-Hours MoversEarnings CalendarUSA Market OverviewCanada Market OverviewEurope Market Overview
  • Trading Ideas
  • News
  • Blog
  • Documentation
    • Documentation CenterVideosIndicatorsPropertiesScreener Market data
  • Popular Articles
    • Bull FlagsRelative StrengthPocket PivotsSupport and ResistanceRSI IndicatorMACD IndicatorPiotroski F-scoreSqueeze PlaysWeinsteinTechnical Breakout SetupsTrading TipsPremarket MoversGap Up StocksBest Dividend StocksBullish Engulfing PatternAscending Triangle PatternSwing TradingAll articles ...
  • Subscriptions
  • Swing Trading Course
  • Account
  • Disclaimer
AffiliatePrivacy
Logo image of BCAC

BROOKLINE CAPITAL ACQUISITIO (BCAC) Stock News

USA - NASDAQ:BCAC - US11374E1047 - Common Stock

22.71 USD
+12.63 (+125.3%)
Last: 7/29/2022, 8:00:01 PM
16.11 USD
-6.6 (-29.06%)
After Hours: 7/29/2022, 8:00:01 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News

BCAC Latest News, Press Relases and Analysis

All
Press Releases
3 years ago - By: Benzinga - Mentions: GHM AVYA TAST THMO ...
News Image

This Communication Services Stock Jumped 149%; Here Are 90 Biggest Movers From Friday

3 years ago - By: Benzinga - Mentions: YRD DSAC CBAN VTGN ...
News Image

Stocks That Hit 52-Week Lows On Friday

7 years ago - By: Xynomic Pharmaceuticals, Inc.
News Image

Xynomic Pharmaceuticals, Inc. Will Present at ASCO 2019 Annual Meeting, Will Sponsor an EU Investigator Meeting for Potentially Pivotal Kidney Cancer Trial, and Appoints Interim Chief Accounting Officer

7 years ago - By: Xynomic Pharmaceuticals, Inc.
News Image

Xynomic Pharma Achieves Important Regulatory Milestones in China and EU in Potentially Pivotal Kidney Cancer and Lymphoma Trials

7 years ago - By: TalkMarkets - Mentions: ASLN
News Image

Week In Review: Nanjing's NJCTTQ Agrees To $4 Billion Package For Abpro Bi-Specific Immunotherapies

7 years ago - By: Xynomic Pharmaceuticals, Inc.
News Image

Xynomic Pharma Doses First South Korean Patient in Phase 3 Renal Cell Carcinoma Trial and Hires Senior Executive Dr. Sophia Paspal to Head Regulatory Affairs and Quality Assurance